Volume 24, Number 4—April 2018
Research
Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017
Table 3
Proportion of influenza A(H7N9) virus survivors with titers at seroprotective levels at acute phase of infection and 3 follow-up points after infection, China, 2017*
Antibody |
% Patients (95% CI) | |||
---|---|---|---|---|
Acute phase |
Follow-up visit 1 |
Follow-up visit 2 |
Follow-up visit 3 |
|
HI | 54.5 (32.2–75.6) | 92.0 (74.0–99.0) | 82.6 (61.2–95.0) | 36.4 (17.2–59.3) |
NI | 50.0 (28.2–71.8) | 96.0 (79.6–99.9) | 91.3 (72.0–98.9) | 63.6 (40.7–82.8) |
MN | 22.7 (7.8–45.4) | 88.0 (68.8–97.5) | 87.0 (66.4–97.2) | 86.4 (65.1–97.1) |
IgG | 45.5 (24.4–67.8) | 100 (86.3–100) | 100 (85.2–100) | 100 (84.6–100) |
IgA | 54.5 (32.2–75.6) | 96.0 (79.6–99.9) | 60.9 (38.5–80.3) | 59.1 (36.4–79.3) |
*Seroprotective levels for HI, NI, and MN titers, >1:40; IgG >1:400; or IgA >1:50. HI, hemagglutination inhibition; MN, microneutralization; NI, neuraminidase inhibition.
1These authors contributed equally to this article.